Diagnostic Innovations in Glaucoma Study: Visual Function

青光眼研究的诊断创新：视觉功能

• 批准号: 7455016
• 负责人: PAMELA A SAMPLE
• 金额: $ 59.97万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-04-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7455016
• 关键词: Address; Affect; African American; Alzheimer' s Disease; American; Animal Model; Apoptotic; Appearance; Biological Neural Networks; Biological Preservation; Blindness; Blood flow; Budgets; Caring; Cell physiology; Cells; Cessation of life; Clinic; Clinical; Clinical Protocols; Clinical Trials; Clinical assessments; Collaborations; Cost Savings; County; Data; Data Analyses; Databases; Development; Diagnosis; Diagnostic; Diagnostic tests; Disease; Doctor of Philosophy; Drops; Early Diagnosis; Effectiveness; End Point; Enrollment; Evaluation; Exclusion Criteria; Eye; Functional disorder; Funding; Future; Gender; Genetic screening method; Glaucoma; Goals; Grant; Health Services Accessibility; Human; Image; Imaging Techniques; In Vitro; Individual; Informatics; Institutes; Joints; Lead; Life; Location; Measurable; Measures; Medical; Methods; Monitor; National Eye Institute; Nerve; Nerve Degeneration; Nerve Fibers; Neuroprotective Agents; Numbers; Ocular Hypertension; Optic Disk; Optic Nerve; Optics; Outcome; Parkinson Disease; Participant; Pathology; Patients; Pattern; Perimetry; Population; Primary Open Angle Glaucoma; Principal Investigator; Procedures; Progress Reports; Progressive Disease; Protocols documentation; Psychophysiology; Purpose; Quality of life; Race; Range; Research; Research Design; Retinal; Retinal Ganglion Cells; Risk; Sample Size; Sampling; Site; Standards of Weights and Measures; Structure; Techniques; Testing; Time; Treatment Effectiveness; Vision; Visual Fields; Week; Work; blind; clinically relevant; concept; cost; demographics; design; follow-up; functional disability; ganglion cell; healthy aging; hypertension treatment; improved; innovation; loss of function; magnocellular; novel therapeutics; optic nerve disorder; parvocellular; prevent; programs; research study; retinal damage; retinal nerve fiber layer; stem

DESCRIPTION: Glaucoma is a progressive disease known to affect the vision in more than 2 million Americans. This estimate is low as individuals with glaucoma are often unaware they have the disease. As people live longer, this number will increase to more than 3 million by 2020 with 120,000 becoming blind in the US. This study has already identified several methods to diagnose the disease earlier and to follow it more effectively. Purpose: In the upcoming grant cycle we propose studies that should further characterize glaucomatous loss using visual function specific testing and new analysis techniques to help us prevent the devastating loss of vision that leads to a substantial drop in quality of life. Aims: To further improve measures to detect the onset and progression of glaucoma and to assess treatment effectiveness using psychophysical measures of visual function. Participants: At least 346 patients with primary open angle glaucoma, 209 at risk for vision loss due to the disease and 100 healthy age-matched controls. A mean long-term follow up of over 7 years is already available for 419 patients to assist in analyses of progressive disease. Methods: 1) Evaluation of several visual function specific tests to further understand the underlying damage to retinal cells important for vision and to determine the progressive loss associated with retinal cell dysfunction and death. 2) Implementation of new testing paradigms and analysis techniques to shorten the time necessary to identify progression of glaucoma. Importance: If the aims of this application are achieved, we will improve our understanding of the different underlying pathologies associated with primary open angle glaucoma, be better able to monitor progression and conversely the effectiveness of treatment, and predict the outcome more effectively for a large number of patients. This should lead to significant changes in our concepts of glaucoma, further enhancements of the methods used in clinical practice to diagnose and follow this disease, and improved clinical protocols for clinical trials of glaucoma therapies.

描述：青光眼是一种进行性疾病，已知影响超过200万美国人的视力。这一估计是低的，因为青光眼患者往往不知道他们患有这种疾病。随着人们寿命的延长，到2020年，这一数字将增加到300多万，美国将有12万人失明。这项研究已经确定了几种方法来早期诊断这种疾病，并更有效地跟踪它。目的：在即将到来的资助周期中，我们提出了一些研究，这些研究应该使用视觉功能特异性测试和新的分析技术来进一步描述昏迷性丧失的特征，以帮助我们预防导致生活质量大幅下降的毁灭性视力丧失。目的：进一步改进青光眼发病和进展的检测措施，并使用视觉功能的心理物理测量来评估治疗效果。参会人员：至少346例原发性开角型青光眼患者，209例有视力丧失风险，100例年龄匹配的健康对照。419例患者的平均长期随访时间超过7年，以协助分析疾病进展。研究方法：1）评估几种视觉功能特异性测试，以进一步了解对视力重要的视网膜细胞的潜在损伤，并确定与视网膜细胞功能障碍和死亡相关的进行性丧失。2)实施新的测试范例和分析技术，以缩短识别青光眼进展所需的时间。重要性：如果本申请的目的得以实现，我们将提高对与原发性开角型青光眼相关的不同潜在病理学的理解，能够更好地监测进展和治疗的有效性，并更有效地预测大量患者的结局。这将导致我们对青光眼的概念发生重大变化，进一步增强临床实践中用于诊断和随访这种疾病的方法，并改善青光眼治疗临床试验的临床方案。